Nociception Level Index After Brachial Plexus Block In Upper Extremity Surgery
2026年5月26日 更新者:Michael Grach、Carmel Medical Center
Nociception Level Index After Brachial Plexus Block In Upper Extremity Surgery: Prospective Comparison Trial
The present prospective within-subject observational study will evaluate whether unilateral brachial plexus block (BPB) induces measurable lateralized autonomic modulation, assesses using bilateral Nociception Level (NoL) monitoring during standardized intraoperative stimuli under general anesthesia.
Regional anesthesia efficacy is traditionally assessed through sensory and motor examination.
However, objective physiologic markers reflecting sympathetic modulation remain limited.
Forty five adults undergoing upper extremity surgery with BPB and general anesthesia, bilateral NoL monitoring will be performed during local anesthetic injection, endotracheal intubation, and nasogastric tube placement.
The primary aim to investigate whether the brachial plexus block induces unilateral modulation of post-operative nervous system activity, assessed by inter-limb differences in NoL values during predefined nociceptive stimuli under general anesthesia.
The secondary aim to evaluate the correlation between postoperative metrics, postoperative pain intensity, and analgesic consumption.
From a clinical perspective, bilateral autonomic monitoring may offer a novel adjunctive method for intraoperative confirmation of block activity, particularly in sedated or anesthetized patients where traditional sensory testing is not feasible.
Furthermore, inter-limb autonomic gradients could represent a future research pathway for objective assessment of regional anesthesia effectiveness beyond subjective pain scores.
調査の概要
状態
募集
条件
詳細な説明
The hypotheses is that brachial plexus block (BPB) would induce an ipsilateral reduction in SANS activity compared to the contralateral side.
The study intervention involved the standard administration of the BPB, a low-risk perineural injection of local anesthetics, conducted under real-time ultrasound guidance and monitored using NoL score measurements on both hands concurrently during endotracheal intubation.
An ultrasound-guided single-shot BPB will be performed using 10 mL of 0.5% bupivacaine (50 mg) in all patients.
The study duration for each participant approximately 5 hours.
All participants undergo induction of general anesthesia using a standardized regimen: midazolam 0.025 mg/kg and fentanyl 0.25 mcg/kg prior to BPB, followed by propofol 2.5 mg/kg, fentanyl 0.75-1 mcg/kg, and rocuronium 0.7 mg/kg.
Subsequently, participants will be intubated (including nasogastric tube placement) and ventilated with maintenance inhalational anesthetics, supplemented by continuous intravenous administration of the short-acting opioid remifentanil at doses of 30-70 ng/kg/min, adjusted according to hemodynamic parameters.
Block efficacy will be assessed using postoperative pain (visual analog scale (VAS)), analgesic consumption, intraoperative analgesic consumption, and NoL measurements in the non-operated hand.
In instances of suboptimal or failed block, all patients in this study will be provided with a backup perioperative analgesic regimen involving continuous intravenous administration of short-acting opioids and remifentanil at doses of 30-70 ng/kg/min .Safety assessments• Pre-anesthetic evaluation and eligibility for general and regional anesthesia• Standard monitoring will be performed according to the American Society of Anesthesiologists (ASA) o Pulse oximetry o Non-invasive blood pressure repeated measurement so 5-lead ECGo End tidal CO2• The principal investigator will assess adverse and serious adverse events, including identification, follow-up, documentation, and reporting to the IRB.
Statistical analysis Primary Endpoint: The statistical null hypothesis posited that there would be no spatial differences in the NoL score measurements following BPB.
Conversely, hypothesized that patients undergoing upper extremity surgery would exhibit lower ipsilateral hand NoL scores than the contralateral hand during noxious stimulation after BBP.
Secondary Endpoints: The null hypothesis proposed that there would be no correlation between the NoL score measurements post-BPB and postoperative pain levels.
Alternative hypothesis that a correlation exists between the contralateral hand NoL scores and postoperative pain levels in patients undergoing upper extremity surgery after BPB.
Sample Size Determination Sample size calculation based on the primary endpoint, defined as the paired difference in NoL values between the blocked (ipsilateral) and contralateral limbs during endotracheal intubation.
Based on preliminary observations and previously reported NoL variability, it is assumed that an expected mean paired difference of approximately 7 units, with a standard deviation of paired differences of 8 units.
Using a two-sided paired t-test with a significance level (alpha) of 0.05 and a statistical power of 80%, a minimum of 34 evaluable subjects will be required.
To account for potential exclusions and incomplete data, 45 participants are planned for enrollment.
Statistical analysis This study will employ a prospective within-subject comparison design.
Continuous variables will be presented as mean ± standard deviation, and categorical variables presented as counts and percentages.
A pragmatic sample size was chosen based on the feasibility of previous NoL studies using within-subject designs.
The study aims to enroll 45 patients to allow paired comparisons between the blocked and contralateral limbs during predefined nociceptive stimuli.
The primary analysis based on paired comparisons of within-subject differences in NoL values between the blocked (ipsilateral) and non-blocked (contralateral) hands for each predefined stimulus (brachial plexus block injection, endotracheal intubation, and nasogastric tube placement).
NoL index measured by a non-invasive probe attached to the index finger (in both arms, the operated hand and the contralateral unoperated arm as control) using an adhesive patch.
The device manufactured by Medasense (Ramat Gan, Israel).
The monitoring module model PMD-200.
The device is indicated for assessing pain levels in unconscious patients.
Paired t-tests were used for the comparisons.
Secondary exploratory analyses will evaluate the correlations between aggregated intraoperative NoL exposure, expressed as the percentage of total monitoring time spent within predefined NoL ranges (lower than 10, 10-25, and higher than 25), and postoperative pain outcomes, including VAS scores and analgesic consumption.
Pearson's correlation coefficients will be calculated for these analyses.
All statistical tests two-sided, and a P value <0.05 will be considered statistically significant.
Variables Independent variables: discrete variable• gender (male/female)• operated hand (left/right)continuous variables:• age (years)• weight (kg)• height (cm)• ASA score Dependent variables: discrete variables• VAS (1-10) continuous variables Anesthesia induction times (HH:MM)• Patient entering the room • Performing BPB • Performing intubation post operative• Nasogastric tube• Induction completed• Surgery and recovery times (HH:MM)• Surgery start• Surgery end• Transfer to Post Anesthetic Care Unit (PACU)• Discharge from PACU• NoL levels difference between right- and left-hands during anesthesia induction• Peak levels differences (NoL index values)• After BPB• After intubation• After nasogastric tube placement• Time of peak levels differences (seconds)• After BPB• After intubation• After nasogastric tube placement• Left-right difference between duration of NoL index higher than 25 (seconds)• NoL levels in non-operated hand from patient entering the operating room to discharge from the PACU (NoL index values temporal variations)• Total time of NoL index higher than 25 (min)• Total time of NoL index between 10-25 (min)• Total time of NoL index lower than 10 (min)• Analgetic treatment • Perioperative total Remifentanil consumption (mg)• Post operative Morphine consumption (mg)• Peri and post operative Non-Steroidal-Anti-Inflammatory Drugs (NSAIDs) consumption• Paracetamol (g)• Ketorolac (mg)• Dipyrone (g)
研究の種類
観察的
入学 (推定)
45
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前:Michael Grach, DR.
- 電話番号:+972506265753
- メール:Grachm@gmail.com
研究連絡先のバックアップ
- 名前:Dana Kosh, Dr.
- 電話番号:972-48250785
- メール:danak@clalit.org.il
研究場所
-
-
-
Haifa、イスラエル、3436212
- 募集
- Carmel Medical Center
-
コンタクト:
- Dana Kosh, Dr.
- 電話番号:972-48250785
- メール:danak@clalit.org.il
-
コンタクト:
- Michael Grach, Dr.
- 電話番号:972506265753
- メール:Grachm@gmail.com
-
主任研究者:
- Michael Grach, Dr.
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
はい
サンプリング方法
確率サンプル
調査対象母集団
forty five patients over 18 years old meeting inclusion criteria
説明
Inclusion Criteria:
- Age >18
- Upper extremity surgery
- Provision of signed and dated informed consent forms
Exclusion Criteria:
- Pregnant women
- Known allergic reaction to bupivacaine or other anesthetic medicine: Midazolam, Fentanyl, Propofol, Rocuronium, Remifentanil, Sevoflurane)
- Known coagulopathy resulting in bleeding tendency
- Thrombocytopenia
- Abnormal laboratory coagulation tests in the previous week = Anticoagulation therapy Participation in other study
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
patient both arms: one operated under brachial plexus block, other serves only as control;
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Comparison ipsilateral and contralateral NoL values in both arms
時間枠:five hours
|
Perioperative NoL score every 5 seconds (physiological parameter measurements, range 0-100) on both arms concurrently, begin before anesthesia induction, till patient will be discharged from PACU, by a non-invasive probe attached to the index finger (in both arms, the operated hand and the contralateral unoperated arm as control) using an adhesive patch.
The device monitoring module model PMD-200 manufactured by Medasense (Ramat Gan, Israel).
|
five hours
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Perioperative pain Assessments and correlations between NoL and VAS values
時間枠:five hours
|
Perioperative pain outcomes, VAS scores by questionnaires, range 1-10 at 3 time points: preoperative, post brachial plexus block and discharge from PACU.
Correlations between VAS and NoL physiological parameter measurements, range 0-100, by a non-invasive probe attached to the index finger (in both arms, the operated hand and the contralateral unoperated arm as control) using an adhesive patch at parallel time points.
Monitoring module model PMD-200 the device manufactured by Medasense (Ramat Gan, Israel).
|
five hours
|
|
Perioperative correlations between total analgesic consumption with VAS and with NoL values
時間枠:Five hours
|
Perioperative correlations between total analgesic consumption with VAS and with NoL values:
|
Five hours
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2023年3月28日
一次修了 (推定)
2026年9月30日
研究の完了 (推定)
2026年9月30日
試験登録日
最初に提出
2026年5月10日
QC基準を満たした最初の提出物
2026年5月26日
最初の投稿 (実際)
2026年6月2日
学習記録の更新
投稿された最後の更新 (実際)
2026年6月2日
QC基準を満たした最後の更新が送信されました
2026年5月26日
最終確認日
2026年3月1日
詳しくは
本研究に関する用語
その他の研究ID番号
- 0110-22-CMC
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
未定
IPD プランの説明
Afer completion of study and publication, data may be concidered to be shared
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。